Putting More People On Statins Would Be Cost Effective and Improve Heart Health

Dr. Ankur Pandya Ph.D. Assistant Professor of Health Decision Science Department of Health Policy and Management Harvard T.H. Chan School of Public Health Boston, MA MedicalResearch.com Interview with:
Dr. Ankur Pandya Ph.D.

Assistant Professor of Health Decision Science
Department of Health Policy and Management
Harvard T.H. Chan School of Public Health
Boston, MA

Medical Research: What is the background for this study? What are the main findings?

Dr. Pandya: The American College of Cardiology and the American Heart Association (ACC-AHA) cholesterol treatment guidelines were controversial when first released in November 2013, with some concerns that healthy adults would be over-treated with statins.

We found that the current 10-year ASCVD risk threshold (≥7.5%) used in the ACC-AHA cholesterol treatment guidelines has an acceptable cost-effectiveness profile (incremental cost-effectiveness ratio of $37,000/QALY), but more lenient ASCVD thresholds would be optimal using cost-effectiveness thresholds of $100,000/QALY (≥4.0%) or $150,000/QALY (≥3.0%).

Medical Research: What should clinicians and patients take away from your report?

Dr. Pandya: It would be cost effective to treat 48-67% of all adults aged 40-75 in the United States with statins.

We found that our results were sensitive to patient preferences for taking a pill daily. Specifically, most patients don’t mind taking a pill daily; for these types of individuals, an ASCVD threshold as low as ≥3.0% (i.e., 67% of adults treated) was cost-effective. But for patients that associate substantial disutility with act of taking a pill daily (disutility of -0.009), the optimal ASCVD threshold could be as high as ≥15.0% (i.e., 39% of adults treated).

Medical Research: What recommendations do you have for future research as a result of this study?

Dr. Pandya: Given the importance of patient preference on the optimal treatment threshold, it would very useful to see more studies that further quantify the quality-of-life impacts of cardiovascular disease prevention efforts (such as a taking a pill daily, other forms of medical treatment, behaviors such as diet and exercise, etc.).

Citation:

Ankur Pandya, Stephen Sy, Sylvia Cho, Milton C. Weinstein, Thomas A. Gaziano. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. JAMA, 2015; 314 (2): 142 DOI: 10.1001/jama.2015.6822

 

Dr. Ankur Pandya Ph.D. (2015). Putting More People On Statins Would Be Cost Effective and Improve Heart Health 

Last Updated on July 14, 2015 by Marie Benz MD FAAD